PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II, specifically developed for sexual dysfunction. PT-141 was designed to retain the sexual function effects of Melanotan II while minimizing tanning and other off-target effects. The peptide activates MC4R receptors in the central nervous system, stimulating sexual desire and arousal through neural pathways rather than vascular mechanisms (unlike PDE5 inhibitors). In 2019, PT-141 (Vyleesi) became the first FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women, representing a novel mechanism of action in sexual medicine.
Key Data
Mechanism of Action
MC3R and MC4R agonist that acts centrally to increase sexual desire without direct vascular effects.
Reported Benefits
All information is presented for Research Use Only (RUO). Not medical advice.